2. Search Result
Search Result
Results for "

B16 F10

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

3

Peptides

9

Inhibitory Antibodies

17

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-168714
    Microtubule inhibitor 12

    		Microtubule/Tubulin Apoptosis Cancer
    Microtubule inhibitor 12 (Compound 2k) is an inhibitor for microtubule polymerization with an IC50 of 22.23 μM. Microtubule inhibitor 12 arrests the cell cycle of B16-F10 at G2/M phase, induces apoptosis in B16-F10, and inhibits cell migration. Microtubule inhibitor 12 inhibits the proliferation of cancer cells B16-f10, A549, HepG2 and MCF-7, with IC50s of 0.098, 0.135, 0.109, and 0.259 μM, respectively. Microtubule inhibitor 12 exhibits antitumor efficacy in mouse model .
    Microtubule inhibitor 12
  • HY-N14221
    Eponemycin

    		Antibiotic DNA/RNA Synthesis Infection Cancer
    Eponemycin is an antibiotic that exhibits antitumor activity. Eponemycin exhibits cytotoxicity in cancer cells B16-F10, L1210, P388 and HCT-116 with IC50 of 0.0017, 0.01, 0.031 and 0.0097 µg/mL, respectively. Eponemycin inhibits the DNA synthesis in B16-F10 and Mitomycin C with IC50 of 0.1 µg/mL and 0.41 µg/mL .
    Eponemycin
  • HY-175014
    LGT-1

    		PD-1/PD-L1 Biochemical Assay Reagents Cancer
    LGT-1 is a PD-L1 ligand. LGT-1 labeled with 18F has an excellent specific uptake in B16-F10 tumor cells, and shows a high tumor uptake but a low liver uptake with good stability in B16-F10 tumor-bearing mice model. LGT-1 can be used as a radiotracer for PET imaging of PD-L1 expression in tumors .
    LGT-1
  • HY-N14435
    Pradimicin Q

    		Antibiotic Fungal Infection
    Pradimicin Q is an antibiotic. The cytotoxicity (IC50) to human colon HCT-116 cells and murine melanoma B16-F10 cells are 75 and 100 μg/mL, respectively .
    Pradimicin Q
  • HY-N9339
    Norglaucine

    (+)-Norglaucine

    		 Others Cancer
    Norglaucine ((+)-Norglaucine), a cytotoxic alkaloid, exhibits cytotoxicity towards the tumor cell lines B16-F10, HepG2, K562 and HL-60 cells .
    Norglaucine
  • HY-162766
    Antitumor agent-184

    		Apoptosis Cancer
    Antitumor agent-184 (compound 12aa) induces cell apoptosis, with the IC50s of 2.35 μM, 7.32 μM and 10.31 μM in B16-F10 cells, 4T1 cells and CT26 cells, respectively .
    Antitumor agent-184
  • HY-155681
    SWS1

    		PD-1/PD-L1 Monoamine Oxidase Cancer
    SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) .
    SWS1
  • HY-149950
    Anticancer agent 106

    		Apoptosis Cancer
    Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
    Anticancer agent 106
  • HY-157323
    HDAC6-IN-28

    		HDAC Apoptosis Cancer
    HDAC6-IN-28 (compound 10C) is a potent inhibitor of HDAC6 with an IC50 of 261 nM. HDAC6-IN-28 significantly induces apoptosis and S-phase arrest in B16-F10 cells. HDAC6-IN-28 efficiently increases the expression of acetylated-α-tubulin in vitro and in vivo .
    HDAC6-IN-28
  • HY-172671
    STING agonist-43

    		STING Cancer
    STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
    STING agonist-43
  • HY-P11026
    DOTA-TMVP1446

    DOTA-PEG4-TMVP1446

    		 VEGFR Cancer
    DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with 68Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .
    DOTA-TMVP1446
  • HY-156092
    Antitumor photosensitizer-4

    		BCRP Apoptosis Cancer
    Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .
    Antitumor photosensitizer-4
  • HY-W001939
    4-Acetylbenzoic acid

    		Biochemical Assay Reagents Cancer
    4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid
  • HY-162962
    IDO1/TDO-IN-7

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model .
    IDO1/TDO-IN-7
  • HY-156085
    LP23

    		PD-1/PD-L1 Cancer
    LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC50: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) .
    LP23
  • HY-N3773
    Dodoviscin A

    		Tyrosinase Cancer
    Dodoviscin A is a pigmentation-altering agent, which can be isolated from the aerial parts of Dodonaea viscosa. Dodoviscin A inhibits melanin production in B16-F10 melanoma cells. Dodoviscin A suppresses mushroom tyrosinase activity, and tyrosinase activity induced by 3-isobutyl-1-methylxanthine. Dodoviscin A also inhibits the phorphosylation of cAMP response element binding protein, induced by 3-isobutyl-1-methylxanthine and forskolin .
    Dodoviscin A
  • HY-W587938
    γ-Eudesmol

    (+)-γ-Eudesmol

    		 Apoptosis Cancer
    γ-Eudesmol ((+)-γ-Eudesmol) is a mitochondrial-mediated apoptosis inducer. γ-Eudesmol binds mitochondrial membrane proteins, triggering depolarization of mitochondrial membrane potential and activating caspase cascades. γ-Eudesmol demonstrates cytotoxicity against multiple tumor cell lines (e.g., HepG2, B16-F10) with IC50 values ranging from 8.86-15.15 μg/mL. γ-Eudesmol is promising for research of cancers, such as hepatocellular carcinoma and melanoma .
    γ-Eudesmol
  • HY-169392
    D5B

    		PD-1/PD-L1 Cancer
    D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .
    D5B
  • HY-W001939R
    4-Acetylbenzoic acid (Standard)

    		Biochemical Assay Reagents Reference Standards Cancer
    4-Acetylbenzoic acid (Standard) is the analytical standard of 4-Acetylbenzoic acid. This product is intended for research and analytical applications. 4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid (Standard)
  • HY-164473
    DETD-35

    		ERK Akt STAT Apoptosis Cancer
    DETD-35 is an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways, which promotes cancer cell apoptosis (Apoptosis) and reduces cancer cell resistance to Vemurafenib (HY-12057). The IC50 values of DETD-35 against wild-type and mutant melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c are 2.7, 6.0, 3.9, 3.1, and 2.5 μM, respectively. DETD-35 holds promise for research in the field of anti-melanoma therapy .
    DETD-35
  • HY-P991468
    IMM20324

    		Interleukin Related Cancer
    IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    IMM20324
  • HY-149523
    Anticancer agent 157

    		Apoptosis NO Synthase Caspase Inflammation/Immunology Cancer
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
    Anticancer agent 157
  • HY-174830
    GJ19

    		PD-1/PD-L1 Cancer
    GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with KD values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy .
    GJ19
  • HY-P990154
    Anti-Mouse TIM-1/CD365 Antibody (3B3)

    		Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Anti-Mouse TIM-1/CD365 Antibody (3B3) is a rat-derived IgG2a κ type agonistic antibody, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3B3) enhances T-cell proliferation and responses by forming a stable TIM-1 complex and bringing TIM-1 into the T-cell receptor (TCR)-CD3 complex. Anti-Mouse TIM-1/CD365 Antibody (3B3) can be used for the researches of cancer, inflammation and immunology, such as experimental autoimmune encephalomyelitis, B16 F10 tumor and transplant .
    Anti-Mouse TIM-1/CD365 Antibody (3B3)
  • HY-P990258
    Anti-Mouse CLEC9A/CD370 Antibody (7H11)

    		Transmembrane Glycoprotein C-type Lectin-like Receptors (CTLRs) Inflammation/Immunology Cancer
    Anti-Mouse CLEC9A/CD370 Antibody (7H11) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CLEC9A/CD370. Anti-Mouse CLEC9A/CD370 Antibody (7H11) reacts with mouse CLEC9A (C-type lectin domain family member 9A) and blocks CLEC9A. Anti-Mouse CLEC9A/CD370 Antibody (7H11) can be used for the researches of cancer and immunology, such as B16.F10-OVA tumor .
    Anti-Mouse CLEC9A/CD370 Antibody (7H11)
  • HY-163534
    PD-1/PD-L1-IN-43

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between PD-1 and PD-L1. PD-1/PD-L1-IN-43 can be used in anti-tumor studies .
    PD-1/PD-L1-IN-43
  • HY-172200
    PD-L1/HDAC6-IN-1

    		PD-1/PD-L1 HDAC Cancer
    PD-L1/HDAC6-IN-1 (Compound HP29) is the inhibitor for PD-L1 and HDAC6 that inhibits the PD-L1/PD-1 interaction and HDAC6 with an IC50 of 26.8 nM and 69 nM. PD-L1/HDAC6-IN-1 enhances the killing ability of Jurkat T cells against HepG2 cells with an IC50 of 3.4 μM. PD-L1/HDAC6-IN-1 exhibits good pharmacokinetics characteristics in rats with a drug exposure of 871.62 ng·h/mL, and exhibits antitumor activity in mouse B16-F10 xenograft models .
    PD-L1/HDAC6-IN-1
  • HY-162275
    JMJD1C-IN-1

    		Histone Demethylase Histone Methyltransferase STAT Cancer
    JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
    JMJD1C-IN-1
  • HY-W272217
    Octacosane

    n-Octacosane; NSC 5549

    		 Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane
  • HY-W004288
    Methyl myristate

    Tetradecanoic acid methyl ester

    		 Drug Derivative Others
    Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl myristate
  • HY-W272217S
    Octacosane-d58

    n-Octacosane-d58; NSC 5549-d58

    		 Bacterial Endogenous Metabolite Cancer
    Octacosane-d58 is the deuterium labeled Octacosane . Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane-d58
  • HY-W272217R
    Octacosane (Standard)

    n-Octacosane (Standard); NSC 5549 (Standard)

    		 Reference Standards Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane (Standard) is the analytical standard of Octacosane. This product is intended for research and analytical applications. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane (Standard)
  • HY-N7587
    Chlorophorin

    		Melanocortin Receptor Metabolic Disease
    Chlorophorin is a inhibitor of Melanocortin Receptor. Chlorophorin reduces tyrosinase activity and inhibits a-melanocyte-stimulating hormone-induced melanin production in B16F10 melanoma cells .
    Chlorophorin
  • HY-125762
    Tyrosinase-IN-16

    		Tyrosinase Cancer
    Tyrosinase-IN-16 (compound 19a) is a tyrosine kinase (Tyrosinase) inhibitor with Ki=470 nM. Tyrosinase-IN-16 is cytotoxic to B16F10 cells, with >90% inhibition at 20 μM .
    Tyrosinase-IN-16
  • HY-163596
    PTPN2-IN-1

    		Phosphatase Cancer
    PTPN2-IN-1 (compound 4) is a PTPN2 inhibitor with the IC50 ≤5 μM. PTPN2-IN-1 inhibits cell growth of B16F10 .
    PTPN2-IN-1
  • HY-W004288S
    Methyl tetradecanoate-d27

    Myristic acid methyl ester-d27

    		 Isotope-Labeled Compounds Drug Derivative Cancer
    Methyl tetradecanoate-d27 is the deuterium labeled Methyl myristate. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl tetradecanoate-d27
  • HY-157123
    Tyrosinase-IN-18

    		Tyrosinase Metabolic Disease
    Tyrosinase-IN-18 (compound 6) is a potent tyrosinase inhibitor. Tyrosinase-IN-18 inhibits melanogenesis in B16F10 mammalian cells. Tyrosinase-IN-18 has strong antioxidant activities against ROS, ABTS +, and DPPH radicals .
    Tyrosinase-IN-18
  • HY-W004288R
    Methyl myristate (Standard)

    Tetradecanoic acid methyl ester (Standard)

    		 Reference Standards Drug Derivative Cancer
    Methyl myristate (Standard) is the analytical standard of Methyl myristate. This product is intended for research and analytical applications. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl myristate (Standard)
  • HY-142955
    Dual photoCORM 1

    		Others Cancer
    Dual photoCORM 1 (compound 5) is metal-free, photochemically active dual CORM. Dual photoCORM 1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach in cancerous B16F10 cells .
    Dual photoCORM 1
  • HY-W708886
    Methyl-d3 tetradecanoate

    		Isotope-Labeled Compounds Drug Derivative Others
    Methyl-d3 tetradecanoate is the deuterium labeled Methyl myristate (HY-W004288). Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl-d3 tetradecanoate
  • HY-160021
    RORγt agonist 4

    		ROR Inflammation/Immunology
    RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .
    RORγt agonist 4
  • HY-151509
    A2-Iso5-2DC18

    		Liposome Cancer
    A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma. .
    A2-Iso5-2DC18
  • HY-P2336A
    CCZ01048 TFA
    3 Publications Verification

    		 Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-P991464
    IBI37G5

    		TNF Receptor Cancer
    IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
    IBI37G5
  • HY-W267446
    6-Methoxy-4-methylcoumarin

    		Melanocortin Receptor GSK-3 Metabolic Disease Cancer
    6-Methoxy-4-methylcoumarin is a 4-methylcoumarin derivative with an antitumor activity. 6-Methoxy-4-methylcoumarin activates melanin synthesis in B16F10 melanoma cells. 6-Methoxy-4-methylcoumarin is a pigmentation stimulator, and can be used for the study of skin conditions such as vitiligo .
    6-Methoxy-4-methylcoumarin
  • HY-P2336
    CCZ01048

    		Melanocortin Receptor Cancer
    CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048
  • HY-161971
    Tyrosinase-IN-35

    		Tyrosinase Cancer
    Tyrosinase-IN-35 (compound 6g) is a human tyrosinase inhibitor (IC50: 2.09 μM), which is more potent than Kojic Acid (HY-W050154) (IC50: 16.38 μM). Tyrosinase-IN-35 can reduce the melanin content of melanoma B16F10 cells in vitro at doses of 4 μM and 8 μM .
    Tyrosinase-IN-35
  • HY-155240
    Tyrosinase-IN-13

    		Tyrosinase Cancer
    Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC50=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10) .
    Tyrosinase-IN-13
  • HY-120241
    Reticulol

    K 251-1

    		 Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-156483
    TT-012
    2 Publications Verification

    		 Others Cancer
    TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .
    TT-012

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: